Epiblastin A

Epiblastin A is an ATP-competitive casein kinase 1 (CK1) inhibitor that inhibits CK1α, CK1δ, and CK1ε. Epiblastin A inhibits the kinase activity of STK10, BRSK1, EEF2K, EGFR, MKNK2, and RIPK2. Epiblastin A inhibits Ki-67 expression, induces Oct4-GFP expression, and enhances the conversion of mouse epiblast stem cells to embryonic stem cells. Epiblastin A selectively reduces the cell viability of colorectal cancer cell lines HCT116, HT29, and DLD1. Epiblastin A can be used in colorectal cancer-related research^[1][2][3]. In Vitro:Epiblastin A (0.5-25 μM; 48 h) dose-dependently inhibits the viability of HT29, HCT116, and DLD1 colorectal cancer cell lines with IC₅₀ values of 6.8, 5.0, and 3.2 μM, respectively, and exhibits no cytotoxicity against normal FHC colon cells^[1].
Epiblastin A promotes the late-stage reprogramming of mouse epiblast stem cells (mEpiSCs) to mouse embryonic stem cells (mESCs), and it inhibits the CK1 family during this late-stage reprogramming process^[2].

Epiblastin A is a potent inhibitor of CK1α, CK1δ, and CK1ε, with the strongest inhibitory potency against CK1δ; it also inhibits STK10 kinase activity^[3].
In Vivo:Epiblastin A (5 mg/kg; i.p.; every 72 h; 45 days) inhibits tumor growth and reduces tumor weight in DLD1-derived tumor xenograft mice by inhibiting CK1α expression^[1].